Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5521602 | 1.00 | LMNA (0.31) | LMNAADRB2ADRB1HTR1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL5074295 | 0.87 | KDM4E (0.35) | LMNAADRB2ADRB1HTR1ASLC6A2 | |
| SCHEMBL14510191 | 0.85 | ADRB1 (0.37) | LMNAADRB2ADRB1HTR1ASLC6A2 | |
| SCHEMBL20675593 | 0.80 | ELANE (0.30) | — | |
| Hydrochloric Acid SCHEMBL5074297 | 0.77 | — | — | |
| SCHEMBL19914256 | 0.72 | HTT (0.43) | — | |
| SCHEMBL5074818 | 0.71 | ALDH1A1 (0.38) | LMNAKDM4ECYP3A4 | |
| SCHEMBL14758281 | 0.69 | PLK4 (0.36) | KDM4E | |
| SCHEMBL5074233 | 0.65 | KMO (0.39) | LMNATSHRKDM4E | |
| SCHEMBL5512753 | 0.65 | KMO (0.39) | LMNATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7081454-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | WITTMAN MARK D | 2006-04-13 | — | — | US | disclosed |
| EP-1545543-A2 | NOVEL TYROSINE KINASES INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| CN-1514833-A | Novel tyrosine kinase inhibitors | ����˹�ж�-����˹˹������˾ | 2004-07-21 | — | — | CN | disclosed |
| WO-2004031401-A2 | NOVEL TYROSINE KINASES INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | ABL1, YES1, FER | LMNA 4571/4885ADRB2 4474/4885ADRB1 3837/4885 |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | ABL1, FER, ERBB2 | LMNA 4678/4885ADRB2 4562/4885ADRB1 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.